EXTENDED RELEASE TABLETS

Brand	Owner	Address	Description
NEXICLON	TRIS PHARMA, INC.	Attn: Jonathan Provoost 3031 US Highway 130 Monmouth Junction NJ 08852	Extended release tablets, extended release chewable tablets and suspension for oral administration of the drug clonidine, intended for the treatment of hypertension, Tourette's syndrome, attention deficit hyperactivity disorder and autism;NEXT I CLONIDINE;
	Where the owner name is not linked, that owner no longer owns the brand

Technical Examples

The abuse potential of a bioavailable drug such as an opiate analgesic agent is reduced and its duration of action is extended by converting it to a poorly absorbed ester prodrug or other prodrug derivative prior to formulation. Unlike many existing sustained release formulations of active pharmaceutical agents wherein an active pharmaceutical agent can be released by chewing, crushing, or otherwise breaking tablets or capsule beads containing the active pharmaceutical agent, such mechanical processing of tablets or capsule beads containing a prodrug of this invention neither releases the active drug nor compromises the controlled conversion of prodrug to drug. Moreover, tablets and capsule beads containing prodrugs of this invention or other drugs can be formulated with a sufficient amount of a thickening agent such as hydroxypropylmethylcellulose or carboxymethylcellulose to impede inappropriate intravenous and nasal administration of formulations that are not indicated for these modes of administration.